PB1767: CHALLENGES IN MACHINE LEARNING-BASED DETECTION OF MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Lars Thielecke(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Ingmar Glauche(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Jonas Schadt(University Hospital Carl Gustav Carus), Ingo Roeder(Helmholtz-Zentrum Dresden-Rossendorf), Friedemann Uschner(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Maximilian Roehnert(University Hospital Carl Gustav Carus), Uta Oelschlaegel(University Hospital Carl Gustav Carus), Malte von Bonin(Städtisches Klinikum Dresden), Martin Bornhäuser(Technische Universität Dresden)
HemaSphere
August 1, 2023
10.1097/01.hs9.0000973924.03429.74
Cited by 0

Related Papers

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
|The Lancet Oncology|2015|402
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
|Leukemia|2011|398
Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection
|Bone Marrow Transplantation|1999|259
Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers
|Leukemia|2001|220
A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
|Blood|2010|177